Symptom Management and Building Your Care Team
At a Glance
While atypical PSP currently has no cure, a multidisciplinary care team can significantly improve quality of life. Treatment focuses on specialized physical therapy for backward falls, speech therapy for safe swallowing, and targeted medications to manage movement, mood, and behavioral symptoms.
Managing atypical PSP requires a shift in perspective. While it is true that there is currently no cure or “disease-modifying” treatment that can stop the progression of the disease [1][2], there are many ways to manage symptoms, maintain independence, and significantly improve quality of life [3]. Success lies in building a multidisciplinary care team—a group of specialists working together to address every facet of the condition [4].
Tip for your first appointment: Bring a list of your current medications, any previous MRI discs (not just the reports), and a written timeline of when your symptoms first started.
Pharmacological Symptom Management
Medication in PSP is often used “off-label” to address specific symptoms rather than the underlying disease [2].
- The Levodopa Trial: For those with the PSP-Parkinsonism (PSP-P) variant, doctors often prescribe levodopa (the primary medication for Parkinson’s disease) [5]. While many patients with atypical PSP see a moderate improvement in stiffness and movement early on, this response is typically “transient,” meaning it may fade after a few years as the disease progresses [6][7].
- Managing Mood and Behavior: Apathy (a loss of interest or motivation) and depression are very common in all forms of PSP [8][9]. These are not just emotional reactions to a diagnosis; they are biological results of the disease [8]. Antidepressants and other neuropsychiatric medications can be highly effective in managing these symptoms [8][10].
- Other Symptoms: Medications can also be used to manage drooling (sialorrhea), sleep disturbances, and pseudobulbar affect (sudden, uncontrollable episodes of crying or laughing) [11][12].
Clinical Trials and Research
Because the underlying cause of PSP involves the tau protein, it shares biological similarities with Alzheimer’s disease. Therefore, research into tau-targeted therapies is ongoing. While standard treatments manage symptoms, you may want to ask your neurologist about participating in clinical trials or observational registries. Engaging in research can offer a sense of agency and hope [13].
The Essential Care Team and Practical Strategies
Because PSP affects movement, speech, and daily living, three types of therapy are considered the “gold standard” of care.
1. Physical Therapy (PT)
PT focuses on maintaining mobility and safety. Unlike other conditions, PSP causes a unique “backwards” instability [14].
- Crucial Warning on Walkers: Do not purchase a standard, lightweight pharmacy walker without a PT evaluation. Because PSP patients tend to fall backward, they often pull lightweight walkers backward on top of themselves, increasing the severity of injuries. A PT will recommend heavily weighted or specialized walkers designed for this specific instability [3][15].
- Managing the “Rocket Sign”: If you experience impulsivity and suddenly stand up without thinking, a PT can teach you strategies like mentally counting to three or tapping your knees before standing [9].
- Unfreezing Gait: For those with PSP-PGF, freezing episodes can be terrifying. Therapists can provide visual cues (like a laser-line cane that gives you a target to step over) or auditory cues (like a metronome) to help “unfreeze” your feet [16].
2. Speech-Language Pathology (SLP)
SLP is essential for managing communication issues and dysphagia (difficulty swallowing) [17].
- Empowering Swallow Safety: Early SLP intervention is critical because swallowing difficulties can lead to aspiration pneumonia (when food or liquid enters the lungs) [17]. Rather than waiting for a crisis, an SLP will teach you proactive, empowering techniques right away—such as the “chin-tuck method” or taking smaller sips—to keep eating safe and enjoyable for as long as possible [18].
3. Occupational Therapy (OT)
OT helps adapt your home environment and daily routines—such as dressing or eating—to maintain independence for as long as possible [3].
Vetting Your Care Team
When meeting with potential specialists, use these questions to ensure they have the expertise needed for atypical PSP:
- “How familiar are you with the 2017 MDS diagnostic criteria for PSP?”
- “Do you have experience treating atypical variants like PSP-P or PSP-PGF specifically, or mostly classic Parkinson’s?”
- “Can you coordinate care with other specialists, like my speech therapist and neurologist?”
- “Are you open to discussing palliative care and quality-of-life goals as the disease progresses?” [13]
Common questions in this guide
Will levodopa help treat my atypical PSP symptoms?
What kind of walker is safe for someone with atypical PSP?
How can physical therapy help with freezing of gait?
When should we get a formal swallow study for atypical PSP?
Are severe mood changes and sudden emotional outbursts normal in atypical PSP?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.How many patients with atypical PSP variants (like PSP-P or PSP-PGF) have you treated before?
- 2.Since we are trying a levodopa trial, how will we measure if it is working, and what signs indicate that it is time to stop or adjust the dose?
- 3.Can you recommend a physical therapist who specifically understands 'backwards' postural instability and the high fall risk in PSP?
- 4.At what stage should we have a formal swallow study to monitor for 'silent aspiration'?
- 5.Are there any clinical trials or research registries currently open that I might qualify for?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (18)
- 1
Which ante mortem clinical features predict progressive supranuclear palsy pathology?
Respondek G, Kurz C, Arzberger T, et al.
Movement disorders : official journal of the Movement Disorder Society 2017; (32(7)):995-1005 doi:10.1002/mds.27034.
PMID: 28500752 - 2
Open-Label Phase 1 Futility Studies of Salsalate and Young Plasma in Progressive Supranuclear Palsy.
VandeVrede L, Dale ML, Fields S, et al.
Movement disorders clinical practice 2020; (7(4)):440-447 doi:10.1002/mdc3.12940.
PMID: 32373661 - 3
Physiotherapy case reports on three people with progressive supranuclear palsy.
Mateus M, Castro Caldas A
Frontiers in aging neuroscience 2023; (15()):1294293 doi:10.3389/fnagi.2023.1294293.
PMID: 38145087 - 4
Multidisciplinary care use in neurodegenerative complex diseases: The example of progressive supranuclear palsy and advanced Parkinson's disease in real-life.
Fabbri M, Ledda C, Schirinzi T, et al.
Parkinsonism & related disorders 2024; (125()):107047 doi:10.1016/j.parkreldis.2024.107047.
PMID: 38964017 - 5
Tremor in progressive supranuclear palsy.
Fujioka S, Algom AA, Murray ME, et al.
Parkinsonism & related disorders 2016; (27()):93-7.
PMID: 27039056 - 6
"Parkinson's disease" on the way to progressive supranuclear palsy: a review on PSP-parkinsonism.
Necpál J, Borsek M, Jeleňová B
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2021; (42(12)):4927-4936 doi:10.1007/s10072-021-05601-8.
PMID: 34532773 - 7
Real-life benefits of intrajejunal levodopa infusion therapy in four patients with the parkinsonian variant of progressive supranuclear palsy: A 1-year follow-up data report.
Metta V, Chaudhuri KR, Leta V, et al.
Brain and behavior 2022; (12(9)):e2547 doi:10.1002/brb3.2547.
PMID: 35943202 - 8
Depression and Apathy across Different Variants of Progressive Supranuclear Palsy.
Bower SM, Weigand SD, Ali F, et al.
Movement disorders clinical practice 2022; (9(2)):212-217 doi:10.1002/mdc3.13396.
PMID: 35146060 - 9
Co-Occurrence of Apathy and Impulsivity in Progressive Supranuclear Palsy.
Kok ZQ, Murley AG, Rittman T, et al.
Movement disorders clinical practice 2021; (8(8)):1225-1233 doi:10.1002/mdc3.13339.
PMID: 34761056 - 10
Interventions in progressive supranuclear palsy.
Koros C, Stamelou M
Parkinsonism & related disorders 2016; (22 Suppl 1()):S93-5.
PMID: 26459661 - 11
Brain gray matter abnormalities in progressive supranuclear palsy revisited.
Pan P, Liu Y, Zhang Y, et al.
Oncotarget 2017; (8(46)):80941-80955 doi:10.18632/oncotarget.20895.
PMID: 29113357 - 12
The Impact of Neuropsychiatric Symptoms in Perceived Quality of Life in Patients With Progressive Supranuclear Palsy.
Morales-Rivero A, Garcia-Cordero I, Khoja A, et al.
European journal of neurology 2025; (32(6)):e70248 doi:10.1111/ene.70248.
PMID: 40525323 - 13
Progressive supranuclear palsy: Neuropathology, clinical presentation, diagnostic challenges, management, and emerging therapies.
DeRosier F, Hibbs C, Alessi K, et al.
Disease-a-month : DM 2024; (70(8)):101753 doi:10.1016/j.disamonth.2024.101753.
PMID: 38908985 - 14
Head position control strategies in progressive Supranuclear Palsy versus Idiopathic Parkinson's Disease during dynamic-on-static platform tilt.
Kammermeier S, Maierbeck K, Dietrich L, et al.
Frontiers in neurology 2024; (15()):1477493 doi:10.3389/fneur.2024.1477493.
PMID: 40308941 - 15
Gait initiation in progressive supranuclear palsy: brain metabolic correlates.
Palmisano C, Todisco M, Marotta G, et al.
NeuroImage. Clinical 2020; (28()):102408 doi:10.1016/j.nicl.2020.102408.
PMID: 33353609 - 16
Association of PSP phenotypes with survival: A brain-bank study.
Guasp M, Molina-Porcel L, Painous C, et al.
Parkinsonism & related disorders 2021; (84()):77-81 doi:10.1016/j.parkreldis.2021.01.015.
PMID: 33581485 - 17
Gray and White Matter Correlates of Dysphagia in Progressive Supranuclear Palsy.
Clark HM, Tosakulwong N, Weigand SD, et al.
Movement disorders : official journal of the Movement Disorder Society 2021; (36(11)):2669-2675 doi:10.1002/mds.28731.
PMID: 34426998 - 18
Dysphagia in progressive supranuclear palsy: A scoping review.
Flynn É, Regan J, Glinzer J, et al.
Clinical parkinsonism & related disorders 2024; (11()):100283 doi:10.1016/j.prdoa.2024.100283.
PMID: 39659393
This page provides general information on managing atypical PSP symptoms for educational purposes. Always consult your neurologist or physical therapy team before changing medications or purchasing mobility aids.
Get notified when new evidence is published on Atypical progressive supranuclear palsy syndrome.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.